Portal venous circulating tumor cells as a biomarker for relapse prediction in resected pancreatic cancer.

ABSTRACT:

Background

Pancreatic cancer is an aggressive disease with poor prognosis. The only potentially curative treatment option is surgical resection, however recurrence is common. Biomarkers to detect minimal residual disease, assist with risk stratification, relapse and real time monitoring, are required. Circulating tumor cells (CTCs) are a promising liquid biopsy biomarker for solid tumors. However, their role in monitoring minimal residual disease in pancreatic cancer remains to be determined. Our study aimed to investigate whether detection and enumeration of CTCs could predict recurrence and provide monitoring of disease status.

Method

Participants planned for Whipple procedure or partial pancreatectomy were enrolled in this prospective pilot study. Intraoperatively, 7.5 mL

SUBMITTER: Yeo D 

PROVIDER: S-EPMC11985722 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature